➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
Boehringer Ingelheim
Medtronic
Harvard Business School

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020825


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020825 describes GEODON, which is a drug marketed by Pfizer and Pfizer Inc and is included in three NDAs. It is available from four suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the GEODON profile page.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.
Summary for 020825
Tradename:GEODON
Applicant:Pfizer
Ingredient:ziprasidone hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020825
Suppliers and Packaging for NDA: 020825
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825 NDA Roerig 0049-0052 0049-0052-60 60 CAPSULE in 1 BOTTLE (0049-0052-60)
GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825 NDA Roerig 0049-0054 0049-0054-60 60 CAPSULE in 1 BOTTLE (0049-0054-60)
Paragraph IV (Patent) Challenges for 020825
Tradename Dosage Ingredient NDA Submissiondate
GEODON CAPSULE;ORAL ziprasidone hydrochloride 020825 2005-02-07

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 20MG BASE
Approval Date:Feb 5, 2001TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 40MG BASE
Approval Date:Feb 5, 2001TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 60MG BASE
Approval Date:Feb 5, 2001TE:ABRLD:Yes

Expired US Patents for NDA 020825

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001   Start Trial   Start Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Baxter
Medtronic
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.